Briefly Bio Funding News – Briefly Bio Raises $1.2M Pre-Seed Funding
Jul 18, 2024 | By Team SR

London-based techbio startup Briefly Bio has secured a $1.2m pre-seed funding round led by Compound VC, with participation from NP Hard, Tiny VC and angel investors across tech and biotech.
Compound VC manages $2B+ for clients who want the personal touch of a trusted advisor and a beautiful digital experience. With over $2 billion in assets under management, Compound Planning is the go-to wealth manager for entrepreneurs, professionals, and retirees who want the personal touch of a trusted advisor accompanied by a beautiful digital experience.
RECOMMENDED FOR YOU
Co-Power Funding News -German Startup Co-Power Secures €6.4 Million Funding
Kailee Rainse
Jun 10, 2025
Zurich’s Rivia Raises €13M Series A To Scale AI Clinical Trial Platform
Kailee Rainse
Mar 18, 2026
Belgium’s Rookoo Raises €900K To Streamline The Global Event Industry
Kailee Rainse
Nov 14, 2025
Harry Rickerby, CEO and co-founder at Briefly Bio, commented: “Scientific methods are a bit like software code; they are a set of instructions that define how an experiment should be run. The majority of this ‘code’ is incomplete, since writing up each experiment completely takes a huge amount of effort. With LLMs, there’s a way to make these methods consistent without imposing on a scientist’s workflow. As Github helped software engineers collaborate and build on each other’s code, we think Briefly can help scientists and engineers do the same with their experiments.”
Dr Gena Nikitin, Founder of Miphic. While Dr Maria Anastasina, Wet Lab Head at the Evolutionary and Synthetic Biology Unit, OIST called this “a revolution in documenting lab experiments.” It is the future of foolproof knowledge-sharing between scientists. Briefly has become a core part of our lab's knowledge base and a great help to me in training researchers and lab management.”
Shelby Newsad, an Investor at Compound, commented:“The crux of successful science lies in consistent and executable methods. Whereas most bio software companies focus on data and its analysis, Briefly goes upstream to the core problem space of reproducibility via protocols. For the first time in science history, this incentivises scientists to share more of their previously tacit knowledge. The fact that Briefly-made methods can be built and collaborated upon creates the unique potential for network effects from their software.”
About Briefly Bio
Founded in 2022, Briefly Bio tool make your lab work reproducible. Capture and share, clearly and consistently. Briefly Bio is building a community of experimental biologists who obsess over the details of doing their science.
Recommended Stories for You
CollimateHealth Raises €6 Million Seed Round to Target Immune Responses with Microbeam Radiation Therapy
Oliver Bennett Jun 15, 2026
Kvantify funding news – Quantum Software Startup Kvantify Secures €10 Million in Seed Funding
Oliver Bennett Jul 3, 2024




